It's important to consider your comfort with risk before diving in.
11d
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...
Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own ...
New data presented at EACR 2026 highlighted anti-tumor activity, improved safety characteristics, and pharmacokinetic ...
The investment seeks is to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index (the “underlying index”) by selling options on leveraged ...
The structural advantages that allow China to conduct clinical trials more quickly and at lower costs should be leveraged to ...
The multipronged approach of Biotechnology Industry Research Assistance Council (BIRAC) encompassing funding, infrastructure, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results